282 related articles for article (PubMed ID: 23574579)
21. Edoxaban in venous thromboembolism and stroke prevention: an appraisal.
Proietti M; Lip GY
Vasc Health Risk Manag; 2016; 12():45-51. PubMed ID: 27013883
[TBL] [Abstract][Full Text] [Related]
22. Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis.
Giustozzi M; Agnelli G; Del Toro-Cervera J; Klok FA; Rosovsky RP; Martin AC; Herold J; Tzoran I; Szmit S; Bertoletti L; Becattini C; Huisman MV
Thromb Haemost; 2020 Jul; 120(7):1128-1136. PubMed ID: 32365386
[TBL] [Abstract][Full Text] [Related]
23. [Treatment of cancer-associated venous thromboembolism].
Di Nisio M
G Ital Cardiol (Rome); 2018 Sep; 19(9 Suppl 1):7S-12S. PubMed ID: 30284557
[TBL] [Abstract][Full Text] [Related]
24. Edoxaban: a new oral direct factor xa inhibitor.
Camm AJ; Bounameaux H
Drugs; 2011 Aug; 71(12):1503-26. PubMed ID: 21861537
[TBL] [Abstract][Full Text] [Related]
25. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
; Büller HR; Décousus H; Grosso MA; Mercuri M; Middeldorp S; Prins MH; Raskob GE; Schellong SM; Schwocho L; Segers A; Shi M; Verhamme P; Wells P
N Engl J Med; 2013 Oct; 369(15):1406-15. PubMed ID: 23991658
[TBL] [Abstract][Full Text] [Related]
26. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study.
Scheres L; Brekelmans M; Ageno W; Ay C; Büller HR; Eichinger S; Hutten BA; Klok FA; Middeldorp S; Schreiber K; Stach K; Blondon M; Delluc A
BJOG; 2018 Nov; 125(12):1581-1589. PubMed ID: 29940089
[TBL] [Abstract][Full Text] [Related]
27. Risk impact of edoxaban in the management of stroke and venous thromboembolism.
Hurst KV; O'Callaghan JM; Handa A
Vasc Health Risk Manag; 2016; 12():329-35. PubMed ID: 27563246
[TBL] [Abstract][Full Text] [Related]
28. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbuchel H; Lanz HJ; Mont L; Morillo CA; Smolnik R; Yin OQP; Kautzner J
Clin Cardiol; 2018 Apr; 41(4):440-449. PubMed ID: 29663464
[TBL] [Abstract][Full Text] [Related]
29. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
Raskob GE; van Es N; Verhamme P; Carrier M; Di Nisio M; Garcia D; Grosso MA; Kakkar AK; Kovacs MJ; Mercuri MF; Meyer G; Segers A; Shi M; Wang TF; Yeo E; Zhang G; Zwicker JI; Weitz JI; Büller HR;
N Engl J Med; 2018 Feb; 378(7):615-624. PubMed ID: 29231094
[TBL] [Abstract][Full Text] [Related]
30. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Ruff CT; Giugliano RP; Braunwald E; Morrow DA; Murphy SA; Kuder JF; Deenadayalu N; Jarolim P; Betcher J; Shi M; Brown K; Patel I; Mercuri M; Antman EM
Lancet; 2015 Jun; 385(9984):2288-95. PubMed ID: 25769361
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial.
Fuji T; Wang CJ; Fujita S; Kawai Y; Nakamura M; Kimura T; Ibusuki K; Ushida H; Abe K; Tachibana S
Thromb Res; 2014 Dec; 134(6):1198-204. PubMed ID: 25294589
[TBL] [Abstract][Full Text] [Related]
32. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial.
Vanassche T; Verhamme P; Wells PS; Segers A; Ageno W; Brekelmans MPA; Chen CZ; Cohen AT; Grosso MA; Medina AP; Mercuri MF; Winters SM; Zhang G; Weitz JI; Raskob GE; Büller HR
Thromb Res; 2018 Feb; 162():7-14. PubMed ID: 29248859
[TBL] [Abstract][Full Text] [Related]
33. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty.
Fuji T; Fujita S; Tachibana S; Kawai Y
J Thromb Haemost; 2010 Nov; 8(11):2458-68. PubMed ID: 20723033
[TBL] [Abstract][Full Text] [Related]
34. Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view.
Barrios V; Escobar C
Expert Rev Cardiovasc Ther; 2015; 13(7):811-24. PubMed ID: 26068539
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
Ruff CT; Giugliano RP; Antman EM; Crugnale SE; Bocanegra T; Mercuri M; Hanyok J; Patel I; Shi M; Salazar D; McCabe CH; Braunwald E
Am Heart J; 2010 Oct; 160(4):635-41. PubMed ID: 20934556
[TBL] [Abstract][Full Text] [Related]
36. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
Gómez-Outes A; Terleira-Fernández AI; Lecumberri R; Suárez-Gea ML; Vargas-Castrillón E
Thromb Res; 2014 Oct; 134(4):774-82. PubMed ID: 25037495
[TBL] [Abstract][Full Text] [Related]
37. Comparison between direct factor Xa inhibitors and low-molecular-weight heparin for efficacy and safety in the treatment of cancer-associated venous thromboembolism: A meta-analysis.
Yang M; Li J; Sun R; Wang Y; Xu H; Yang B; Wu X; Yu L
J Cancer Res Ther; 2019; 15(7):1541-1546. PubMed ID: 31939435
[TBL] [Abstract][Full Text] [Related]
38. Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction).
Aisenberg J; Chatterjee-Murphy P; Friedman Flack K; Weitz JI; Ruff CT; Nordio F; Mercuri MF; Choi Y; Antman EM; Braunwald E; Giugliano RP
Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e003998. PubMed ID: 29748353
[TBL] [Abstract][Full Text] [Related]
39. Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial.
Carcas AJ; Borobia AM; Velasco M; Abad-Santos F; Díaz MQ; Fernández-Capitán C; Ruiz-Giménez N; Madridano O; Sillero PL;
Trials; 2012 Dec; 13():239. PubMed ID: 23237631
[TBL] [Abstract][Full Text] [Related]
40. New oral anticoagulants in the treatment of acute venous thromboembolism - a systematic review with indirect comparisons.
Hirschl M; Kundi M
Vasa; 2014 Sep; 43(5):353-64. PubMed ID: 25147012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
